{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T22:18:12Z","timestamp":1773526692949,"version":"3.50.1"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2018,9,17]],"date-time":"2018-09-17T00:00:00Z","timestamp":1537142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"},{"start":{"date-parts":[[2018,9,17]],"date-time":"2018-09-17T00:00:00Z","timestamp":1537142400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Despite major advances in the treatment of chronic heart failure (HF) with reduced ejection fraction (HFrEF), morbidity and mortality associated with the condition remain high, suggesting the need for additional treatment options, particularly haemodynamically neutral treatments that do not alter blood pressure, heart rate, or renal function. HF with preserved ejection fraction (HFpEF) is also associated with high morbidity and mortality and adequate treatment options are limited; thus there is a critical unmet need for the development of novel therapies for HFpEF. Chronic HFrEF and HFpEF are both systemic disorders that affect not only the heart but several other tissues and organs including skeletal muscle, leading to exercise intolerance and dyspnoea. Partial adenosine A1-receptor agonists represent a novel potential therapy for HF regardless of underlying ejection fraction given their minimal effect on heart rate and blood pressure, and preclinical data demonstrate several possible beneficial mechanisms, including improved mitochondrial function and sarcoplasmic reticulum Ca2+-ATPase (SERCA2a) activity, enhanced energy substrate utilization, reverse ventricular remodelling, and anti-ischemic, cardioprotective properties. However, data on this class of drugs in humans are scarce, and the optimal dose of the partial adenosine A1 receptor, neladenoson bialanate, has not been defined. Here we describe the design and rationale of two randomized, double-blind, placebo-controlled, parallel-group, dose-finding phase 2b trials, PANTHEON (HFrEF) and PANACHE (HFpEF), that will advance our understanding of the potential benefit and optimal dose of neladenoson bialanate and provide critical information for the planning of future phase 3 trials.<\/jats:p>","DOI":"10.1002\/ejhf.1295","type":"journal-article","created":{"date-parts":[[2018,9,18]],"date-time":"2018-09-18T02:40:08Z","timestamp":1537238408000},"page":"1601-1610","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Rationale and Design of the Phase 2B Clinical Trials to Study the Effects of the Partial Adenosine A1-Receptor Agonist Neladenoson Bialanate in Patients with Chronic Heart Failure with Reduced (Pantheon) and Preserved (Panache) Ejection Fraction"],"prefix":"10.1093","volume":"20","author":[{"given":"Adriaan A.","family":"Voors","sequence":"first","affiliation":[{"name":"Department of Cardiology, University of Groningen, University Medical Center Groningen , Groningen ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjiv J.","family":"Shah","sequence":"additional","affiliation":[{"name":"Feinberg Cardiovascular Research Institute, Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine , Chicago, IL ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeroen J.","family":"Bax","sequence":"additional","affiliation":[{"name":"Leiden University Medical Center , Leiden ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Mississippi , Jackson, MS ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mihai","family":"Gheorghiade","sequence":"additional","affiliation":[{"name":"Feinberg Cardiovascular Research Institute, Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine , Chicago, IL ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian F.","family":"Hernandez","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University , Durham, NC ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dalane W.","family":"Kitzman","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Sections on Cardiovascular Medicine and Geriatrics, Wake Forest School of Medicine , Winston-Salem, NC ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John J.V.","family":"McMurray","sequence":"additional","affiliation":[{"name":"British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonieta Bomfim","family":"Wirtz","sequence":"additional","affiliation":[{"name":"Bayer AG , Leverkusen ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivian","family":"Lanius","sequence":"additional","affiliation":[{"name":"Bayer AG , Leverkusen ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"van der Laan","sequence":"additional","affiliation":[{"name":"Bayer AG , Leverkusen ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott D.","family":"Solomon","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Brigham and Women's Hospital , Boston, MA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,9,17]]},"reference":[{"key":"2026011721255379600_ejhf1295-bib-0001","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","article-title":"Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026011721255379600_ejhf1295-bib-0002","first-page":"e240","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines","volume":"128","author":"Yancy","year":"2013","journal-title":"Circulation"},{"key":"2026011721255379600_ejhf1295-bib-0003","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1161\/CIR.0000000000000509","article-title":"2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines and the Heart Failure Society of America","volume":"136","author":"Yancy","year":"2017","journal-title":"Circulation"},{"key":"2026011721255379600_ejhf1295-bib-0004","first-page":"897","article-title":"Heart failure with preserved ejection fraction","volume":"376","author":"Redfield","year":"2017","journal-title":"N Engl J Med"},{"key":"2026011721255379600_ejhf1295-bib-0005","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1161\/CIRCULATIONAHA.116.021884","article-title":"Phenotype-specific treatment of heart failure with preserved ejection fraction: a multiorgan roadmap","volume":"134","author":"Shah","year":"2016","journal-title":"Circulation"},{"key":"2026011721255379600_ejhf1295-bib-0006","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa0912613","article-title":"Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure","volume":"363","author":"Massie","year":"2010","journal-title":"N Engl J Med"},{"key":"2026011721255379600_ejhf1295-bib-0007","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/164_2016_83","article-title":"Partial adenosine A1 agonist in hart failure","volume":"243","author":"Dinh","year":"2017","journal-title":"Handb Exp Pharmacol"},{"key":"2026011721255379600_ejhf1295-bib-0008","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s10741-015-9522-7","article-title":"Partial adenosine A1 receptor agonism: a potential new therapeutic strategy for heart failure","volume":"21","author":"Greene","year":"2016","journal-title":"Heart Fail Rev"},{"key":"2026011721255379600_ejhf1295-bib-0009","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1161\/01.RES.75.3.434","article-title":"Relation between myocardial function and expression of sarcoplasmic reticulum Ca2+-ATPase in failing and nonfailing human myocardium","volume":"75","author":"Hasenfuss","year":"1994","journal-title":"Circ Res"},{"key":"2026011721255379600_ejhf1295-bib-0010","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1161\/CIRCHEARTFAILURE.112.000208","article-title":"Chronic therapy with a partial adenosine A1-receptor agonist improves left ventricular function and remodeling in dogs with advanced heart failure","volume":"6","author":"Sabbah","year":"2013","journal-title":"Circ Heart Fail"},{"key":"2026011721255379600_ejhf1295-bib-0011","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/cmdc.201700151","article-title":"Neladenoson bialanate hydrochloride: a prodrug of a partial adenosine A1 receptor agonist for the chronic treatment of heart diseases","volume":"12","author":"Meibom","year":"2017","journal-title":"Chem Med Chem"},{"key":"2026011721255379600_ejhf1295-bib-0012","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/jcph.828","article-title":"Safety and tolerability of neladenoson bialanate, a novel oral partial adenosine A1 receptor agonist, in patients with chronic heart failure","volume":"57","author":"Voors","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"2026011721255379600_ejhf1295-bib-0013","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/ejhf.800","article-title":"Patient-reported outcomes in the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED ejection fraction (SOCRATES-PRESERVED) study","volume":"19","author":"Filippatos","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026011721255379600_ejhf1295-bib-0014","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1161\/CIRCHEARTFAILURE.113.000359","article-title":"Comparable performance of the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with preserved and reduced ejection fraction","volume":"6","author":"Joseph","year":"2013","journal-title":"Circ Heart Fail"},{"key":"2026011721255379600_ejhf1295-bib-0015","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1001\/jamacardio.2017.3983","article-title":"Association of serial Kansas City Cardiomyopathy Questionnaire assessments with death and hospitalization in patients with heart failure with preserved and reduced ejection fraction: a secondary analysis of 2 randomized clinical trials","volume":"2","author":"Pokharel","year":"2017","journal-title":"JAMA Cardiol"},{"key":"2026011721255379600_ejhf1295-bib-0016","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.apmr.2016.08.481","article-title":"Association between 6-minute walk test distance and objective variables of functional capacity after exercise training in elderly heart failure patients with preserved ejection fraction: a randomized exercise trial","volume":"98","author":"Maldonado-Martin","year":"2017","journal-title":"Arch Phys Med Rehabil"},{"key":"2026011721255379600_ejhf1295-bib-0017","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.cardfail.2015.09.014","article-title":"How B-type natriuretic peptide (BNP) and body weight changes vary in heart failure with preserved ejection fraction compared with reduced ejection fraction: secondary results of the HABIT (HF assessment with BNP in the home) trial","volume":"22","author":"Maisel","year":"2016","journal-title":"J Card Fail"},{"key":"2026011721255379600_ejhf1295-bib-0018","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jchf.2016.11.015","article-title":"Interaction between spironolactone and natriuretic peptides in patients with heart failure and preserved ejection fraction: from the TOPCAT trial","volume":"5","author":"Anand","year":"2017","journal-title":"JACC Heart Fail"},{"key":"2026011721255379600_ejhf1295-bib-0019","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1002\/ejhf.274","article-title":"Changes in N-terminal pro-B-type natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction: an analysis of the I-Preserve study","volume":"17","author":"Jhund","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2026011721255379600_ejhf1295-bib-0020","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004281","article-title":"Making the case for skeletal muscle myopathy and its contribution to exercise intolerance in heart failure with preserved ejection fraction","volume":"10","author":"Kitzman","year":"2017","journal-title":"Circ Heart Fail"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fejhf.1295","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/20\/11\/1601\/66267962\/eurjhf_20_11_1601.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/20\/11\/1601\/66267962\/eurjhf_20_11_1601.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T02:27:57Z","timestamp":1768703277000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/20\/11\/1601\/8414523"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,17]]},"references-count":20,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2018,9,17]]},"published-print":{"date-parts":[[2018,11,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.1295","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,11]]},"published":{"date-parts":[[2018,9,17]]},"assertion":[{"value":"2018-05-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-07-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-09-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}